Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.100 GeneticVariation disease BEFREE We attempted to gain insight into the potential contribution of ovarian cancer genomic instability resulted from TP53 mutation to the aberrant expression of multidrug resistance gene MDR1. 28148293 2017
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.100 Biomarker disease BEFREE The finding that the compound induced significantly more cell death in Pgp/MDR1 overexpressing OC cells compared to vincristine and paclitaxel warrants further development of the compound as a new therapy for OC patients with treatment refractory tumors and/or relapsing disease. 28496304 2017
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.100 Biomarker disease BEFREE The goal of this study is to evaluate the ability of HA-PEI/HA-PEG to deliver MDR1 siRNA and the efficacy of the combination of HA-PEI/HA-PEG/MDR1 siRNA with paclitaxel to suppress growth of ovarian cancer. 25687880 2015
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.100 AlteredExpression disease BEFREE Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer. 25515492 2015
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.100 Biomarker disease BEFREE The MDR1 gene is a direct target of the Wnt/β-catenin signaling pathway, which plays an important role in ovarian cancer. 26053275 2015
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.100 Biomarker disease BEFREE Cosilencing of PKM-2 and MDR-1 Sensitizes Multidrug-Resistant Ovarian Cancer Cells to Paclitaxel in a Murine Model of Ovarian Cancer. 25964202 2015
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.100 GeneticVariation disease BEFREE These preclinical data suggest that a fiber-modified adenovirus vector under the control of the MDR1 promoter represents a promising treatment strategy for platinum-pretreated ovarian cancer as a single agent or in combination with conventional anticancer drugs. 22209976 2012
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.100 Biomarker disease BEFREE Downregulation of gene MDR1 by shRNA to reverse multidrug-resistance of ovarian cancer A2780 cells. 22842366 2012
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.100 Biomarker disease BEFREE Our data point at IMP-1 and MDR1 as indicators for response to therapy, and at IMP-1 as a novel therapeutic target for overcoming multidrug resistance of ovarian cancer. 21618519 2012
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.100 Biomarker disease BEFREE The aim of this study was to evaluate the effect of a MDR1 targeted fiber-modified CRAd against chemotherapy resistant ovarian cancer. 21741695 2011
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.100 GeneticVariation disease BEFREE ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. 18765553 2008
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.100 GeneticVariation disease BEFREE The mdr-1 polymorphism G2677T/A in exon 21 correlates with the paclitaxel response in ovarian cancer and may be important for the function of P-glycoprotein and resistance to paclitaxel and provide useful information for individualized therapy. 16467099 2006
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.100 AlteredExpression disease BEFREE The drug concentrations applied referred to clinical relevant doses. mdr1 mRNA expression was significantly higher in specimens from recurrent ovarian cancer incubated in paclitaxel than in specimens from chemotherapy-naive ovarian cancer. 17001177 2006
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.100 Biomarker disease BEFREE Coinhibition of both Src and MDR-1 synergistically enhanced paclitaxel-induced cytotoxicity in paclitaxel-resistant ovarian cancer cell lines. 16288028 2005
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.100 AlteredExpression disease BEFREE Caveolin-1 expression in ovarian carcinoma is MDR1 independent. 11863219 2002
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.100 Biomarker disease BEFREE The ovarian carcinoma cell line SKOV3 transducted with a human multidrug resistance gene (mdr1) served as the drug resistant model (SKOV3/mdr1). 11780384 2001
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.100 GeneticVariation disease BEFREE To fill this gap, we investigated the rate of gene amplification of the mdr1-gene in 63 recurrent ovarian carcinomas and we determined the resistance pattern of these cells using an ex vivo assay. 10656626 1999
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.100 AlteredExpression disease BEFREE Co-expression of the MDR1 gene and HSP27 in human ovarian cancer. 9713493 1998
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.100 AlteredExpression disease BEFREE A reduction in mdr-1 expression after 8-Cl-cAMP treatment was also observed in multidrug-resistant human ovarian cancer cell lines. 7543490 1995
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.100 AlteredExpression disease BEFREE The presence of even very low levels of MDR1 mRNA correlated with the lack of response to MDR regimens in these tumor types (P < .035 for ovarian carcinomas, P < .029 for SCLCs, and P < .0005 for both tumor types; Fisher's Exact Test). 1359152 1992
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.100 AlteredExpression disease BEFREE Although drug resistance is a major problem in treatment of ovarian cancer, resistance to the drugs most active against these tumors probably occurs through a mechanism other than expression of the MDR1 gene product. 1973872 1990
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary
0.100 AlteredExpression disease BEFREE These results favor the expression of the MDR1 gene as one of the determinants involved in the acquired chemoresistance of ovarian cancers. 2766278 1989